Authors
Takaya Uno, Kouichi Hosomi, Satoshi Yokoyama
Published in
International journal of clinical pharmacology and therapeutics. Oct 07, 2026. Epub Oct 07, 2026.
Abstract
To identify the time-to-onset profiles of amiodarone-induced interstitial lung disease using two spontaneous adverse event reporting databases.
Data were obtained from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS; JAPIC AERS) and the Japanese Adverse Drug Event Report database (JADER). Time-to-onset profiles of amiodarone-induced interstitial lung disease were analyzed using the generalized Wilcoxon test. Additionally, because JADER allows estimation of body fat percentage (eBF%), a one-sided Jonckheere-Terpstra test was conducted to evaluate the relationship between eBF% and time-to-onset of amiodarone-induced interstitial lung disease.
In FAERS, sex was not significantly associated with the median time-to-onset of interstitial lung disease (male: 187 days; female: 190 days; p = 0.8457). Conversely, in JADER, female patients demonstrated a significantly longer median time-to-onset than male patients (male: 175 days; female: 273 days; p = 0.0214). Furthermore, in the Jonckheere-Terpstra test, patient stratification into healthy weight, overweight, and obesity categories based on eBF% showed a significant increase in median onset time with increasing obesity level in male patients (healthy weight: 96 days; overweight: 185 days; obesity: 272 days; p = 0.0126) but not in female patients (healthy weight: 253 days; overweight: 273 days; obesity: 428.5 days; p = 0.4123).
To prevent fatal outcomes, pulmonary function may need to be monitored according to race, sex, and obesity level.
PMID:
42839842
Bibliographic data and abstract were imported from PubMed on 07 Oct 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 19
- Comments 0